MGI, a subsidiary of the BGI Group, announced today that Duncan Yu, President of MGI and Executive Vice President of BGI, and Hui Jiang, Chief Operating Officer of MGI and Vice President of BGI Research, have been invited to present during the upcoming 37th J.P. Morgan Healthcare Conference in January.
JPM Conference China Track
Date: Wednesday, January 9, 2019
Time of MGI Presentation: 8:30 a.m.
Speaker: Duncan Yu, Executive Vice President of BGI and President of MGI
Location: Westin St. Francis Hotel
335 Powell St, San Francisco, CA 94102
China Focus@JPM Week
Date: Sunday, January 6, 2019
Time of MGI Presentation: 2:15 p.m.
Speaker: Hui Jiang, Chief Operating Officer of MGI and Vice President of BGI Research
Location: JW Marriott San Francisco Union Square
515 Mason Street, 2nd Floor, San Francisco, CA 94102
MGI is an innovative life science company that produces sequencing devices, equipment, consumables and reagents to support life science research, medicine and healthcare, based on its own proprietary technologies, including those pioneered by Complete Genomics, a Silicon Valley company acquired by BGI in 2013 and now part of MGI. Carrying on BGI's mission of "Omics for All" to advance life science for the benefit of mankind, MGI is committed to lowering barriers to access in genomics and enabling more effective and affordable healthcare packages for all. MGI’s multi-omics platforms include genetic sequencing, mass spectrometry and medical imaging. Using patented DNA nanoball NGS technology (DNBseqTM), including DNB library construction, patterned error-free array, and optimized Combinatorial Probe-Anchor Synthesis (cPAS), MGI sequencers produce highly accurate and cost-effective results with a variety of throughputs for a wide range of applications.
With its newly released sequencer model MGISEQ-T7, the most powerful sequencer released to date, MGI takes genome sequencing to a new level with a daily output of data up to 6Tb, significantly shortening the time and reducing the cost of population genome projects. Combining its high throughput DNBseqTM NGS technology with an advanced proprietary barcoding of NGS reads (stLFR technology, bioRxiv), MGI is revolutionizing whole genome sequencing (WGS).
Partners and customers around the world who have been using the MGI platform have recognized its distinct advantages.
"We decided to collaborate with BGI and use all the technology that has been developed by MGI," said Dr. Mathias Uhlén, Professor of Microbiology at Royal Institute of Technology (KTH), founding director of Science for Life Laboratory (SciLifeLab), and senior researcher of Karolinska Institutet in Sweden. "So far, we are very happy with the quality of the data from the project, and it is the best quality we have ever seen."
"MGI is the first company that can achieve affordable and essentially error-free genome sequencing," said Dr. George Church, Professor of Genetics, and Health Sciences and Technology of Harvard and MIT.